Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as... see more

Recent & Breaking News (NDAQ:PULM)

Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering

PR Newswire April 8, 2019

Thinking about buying stock in Cronos Group Inc., Facebook Inc., InspireMD Inc., Pulmatrix Inc., or Sangamo Therapeutics?

PR Newswire April 2, 2019

Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole

PR Newswire April 1, 2019

Pulmatrix to Participate in Upcoming Investor Conferences

PR Newswire March 14, 2019

Pulmatrix Regains NASDAQ Compliance

PR Newswire March 12, 2019

Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline

PR Newswire February 19, 2019

Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs

PR Newswire February 12, 2019

Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market

PR Newswire February 8, 2019

Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study

PR Newswire February 7, 2019

Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1

PR Newswire February 6, 2019

Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split

PR Newswire February 5, 2019

Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock

PR Newswire February 5, 2019

Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock

PR Newswire January 31, 2019

Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock

PR Newswire January 30, 2019

Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire January 30, 2019

Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock

PR Newswire January 28, 2019

Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire January 28, 2019

Pulmatrix Announces $3.0 Million Registered Direct Offering

PR Newswire November 29, 2018

Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

PR Newswire November 21, 2018

Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology

PR Newswire November 15, 2018